

February 15, 2023
Sawai Pharmaceutical Co., Ltd.

Sawai Receives Approvals for Three Generic Drugs with 10 Strengths

Osaka, Japan – February 15, 2023 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Kenzo Sawai) received approvals by the Ministry of Health, Labour and Welfare for three generic drugs with 10 strengths. The three compounds marked with an asterisk below are approved for the first time as generics.

The list of approved products:

1. Azilsartan Tablets, OD Tablets

Generic name:	Azilsartan*	Strengths:	Tablets: 10mg, 20mg, 40mg OD Tablets: 10mg, 20mg, 40mg
Brand products:	AZILVA [®] Tablets 10mg, 20mg, 40mg		

2. Zinc Acetate Tablets

Generic name:	Zinc Acetate Hydrate*	Strengths:	25mg, 50mg
Brand products:	NOBELZIN [®] Tablets 25mg, 50mg		

3. Lenalidomide Capsules

Generic name:	Lenalidomide*	Strengths:	2.5mg, 5mg
Brand products:	Revlimid [®] Capsules 2.5mg, 5mg		

The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.

◆ Contact Information ◆

Public Relations Office, Sawai Pharmaceutical Co., Ltd.

E-mail : koho@sawai.co.jp